Company Analysis
Sign in

Neumora Therapeutics, Inc. (NMRA)

Nasdaq: NMRA · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.7
◀ Past 3.4● Present 4.1▶ Future 5.9
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

19 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Neumora Therapeutics, Inc.’s names, not what it holds today.

Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 9 in 2024 and 7 in 2023
Applications published
21
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Computer technology8
Medical technology5
Pharmaceuticals5
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
NEUMORA THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
20 published
Neumora Therapeutics, Inc. its own name
US, as the owner printed on each patent
19 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 29, 202512,371,414Methods of treating neurological disordersPharmaceuticalsNeumora Therapeutics, Inc.
Mar 11, 202512,247,0371-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disordersOrganic fine chemistryNeumora Therapeutics, Inc.
Feb 25, 202512,232,848System and method of facial analysisComputer technologyNeumora Therapeutics, Inc.
Dec 24, 202412,171,758Crystalline salt forms of kappa opioid receptor antagonist and products and methods related theretoPharmaceuticalsNeumora Therapeutics, Inc.
Nov 26, 202412,152,038Vasopressin receptor antagonists and products and methods related theretoPharmaceuticalsNeumora Therapeutics, Inc.
Sep 10, 202412,087,446Multimodal dynamic attention fusionComputer technologyNeumora Therapeutics, Inc.
Jun 4, 202412,002,590Machine learning-based diagnostic classifierMedical technologyNeumora Therapeutics, Inc.
May 28, 202411,993,580Methods of treating neurological disordersPharmaceuticalsNeumora Therapeutics, Inc.
Mar 26, 202411,942,224System and method for identifying transdiagnostic features shared across mental health disordersMedical technologyNeumora Therapeutics, Inc.
Jan 30, 202411,887,724Estimating uncertainty in predictions generated by machine learning modelsComputer technologyNeumora Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0304560MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODSOrganic fine chemistryNEUMORA THERAPEUTICS, INC.
Mar 6, 20252025/0074888PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODSPharmaceuticalsNEUMORA THERAPEUTICS, INC.
Dec 19, 20242024/0415433SYSTEMS AND METHODS FOR DETECTING ANXIETY USING EEGMedical technologyNEUMORA THERAPEUTICS, INC.
Oct 24, 20242024/0355480SYSTEM AND METHOD FOR IDENTIFYING TRANSDIAGNOSTIC FEATURES SHARED ACROSS MENTAL HEALTH DISORDERSMedical technologyNEUMORA THERAPEUTICS, INC.
Sep 5, 20242024/0294492METHODS OF TREATING NEUROLOGICAL DISORDERSPharmaceuticalsNEUMORA THERAPEUTICS, INC. · patent 12,371,414 granted from it
Jul 25, 20242024/0246928METHODS OF TREATING NEUROLOGICAL DISORDERSPharmaceuticalsNEUMORA THERAPEUTICS, INC. · patent 11,993,580 granted from it
Jul 4, 20242024/0221950MULTI-MODAL INPUT PROCESSINGMedical technologyNEUMORA THERAPEUTICS, INC.
Jun 20, 20242024/0197220SYSTEMS AND METHODS FOR SCREENING, DIAGNOSING, AND STRATIFYING PATIENTSMedical technologyNEUMORA THERAPEUTICS, INC.
Apr 25, 20242024/0136058MACHINE LEARNING SYSTEMS FOR ANCHORING DIMENSIONS OF LATENT SPACESComputer technologyNEUMORA THERAPEUTICS, INC.
Feb 22, 20242024/0062847METHODS AND SYSTEMS FOR COMPUTER-GENERATED PREDICTIVE APPLICATION OF NEUROIMAGING AND GENE EXPRESSION MAPPING DATAComputer technologyNEUMORA THERAPEUTICS, INC.
What it applied for, 2024 to 2025: Medical technology 4 · Computer technology 3 · Pharmaceuticals 3 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NMRA · research, not advice